Serotonin–norepinephrine reuptake inhibitor: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 32: Line 32:


{{stub}}
{{stub}}
<gallery>
File:Duloxetine.svg|Duloxetine
File:Timeline-SNRIs-2010.png|Serotonin–norepinephrine reuptake inhibitor
File:Desvenlafaxine.svg|Desvenlafaxine
File:Duloxetine.svg|Duloxetine
File:Levomilnacipran.svg|Levomilnacipran
File:Milnacipran structure.svg|Milnacipran
File:Sibutramine.svg|Sibutramine
File:Tramadol.svg|Tramadol
File:Venlafaxine structure.svg|Venlafaxine
File:Timeline-history-2010.png|Serotonin–norepinephrine reuptake inhibitor
File:SynapseSchematic en.svg|Serotonin–norepinephrine reuptake inhibitor
File:Aryloxypropanamine scaffold.svg|Serotonin–norepinephrine reuptake inhibitor
</gallery>

Latest revision as of 01:00, 20 February 2025

Serotonin–Norepinephrine Reuptake Inhibitor

The Serotonin–Norepinephrine Reuptake Inhibitor (SNRI) is a class of antidepressant drugs that treat major depressive disorder, anxiety disorders, obsessive-compulsive disorder (OCD), social phobia, attention-deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. SNRIs work by increasing the levels of serotonin and norepinephrine in the brain by inhibiting their reuptake into cells.

Etymology[edit]

The term "Serotonin–Norepinephrine Reuptake Inhibitor" is derived from the drug's mechanism of action. It inhibits the reuptake of the neurotransmitters serotonin and norepinephrine, thereby increasing their levels in the brain.

History[edit]

The first SNRI, venlafaxine, was introduced by Wyeth in 1993. The FDA approved it for the treatment of depression, and later for anxiety disorders and certain types of pain. Following venlafaxine, the next SNRI to be approved was duloxetine (Cymbalta) by Eli Lilly in 2004. Duloxetine was approved for the treatment of major depression and neuropathic pain.

Mechanism of Action[edit]

SNRIs work by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine. This results in an increase in the extracellular concentrations of these neurotransmitters and therefore an increase in neurotransmission.

Related Terms[edit]

See Also[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia